Rodman & Renshaw Global Healthcare Conference 2008 takes place May
19-20, 2008 at the Le Meridien Beach Plaza Hotel, in Monte Carlo,
Monaco. In-depth information about the event is available at http://www.rodmanandrenshaw.com/conferences?id=18&link=confinfo.
Business Wire is the official news wire for the Rodman & Renshaw Global
Healthcare Conference. Listed below are profiles from the conference
presenters. Breaking news releases and photos are available at http://www.tradeshownews.com,
Business Wire's trade show, conference, and event news resource.
|
Company:
|
Access Pharmaceuticals, Inc.
|
|
Ticker Symbol & Exchange:
|
ACCP.OB
|
|
Investor Relations Contact:
|
Stephen B. Thompson
|
|
Investor Relations Contact Phone:
|
214-905-5100
|
|
Web:
|
www.accesspharma.com
|
|
Date of Presentation:
|
Monday, May 19, 2008
|
|
|
|
|
Access Pharmaceuticals, Inc. (ACCP.OB) is an emerging pharmaceutical
company focused on the development and commercialization of
proprietary products for the treatment and supportive care of cancer
patients. Access has one approved product, MuGard™
for the management of oral mucositis. The company’s
lead oncology product is ProLindac™, a
polymer-linked platinum cancer drug, which is in Phase 2 clinical
testing in recurrent ovarian cancer patients. Angiolix®,
an antiangiogenic humanized monoclonal antibody, and Prodrax®,
a hypoxia-activated prodrug, are the company’s
lead preclinical oncology products. Access is also developing oral
insulin and oral hGH using its proprietary Cobalamin™
oral drug delivery technology.
|
|
|
|
|
Company:
|
Active Biotech AB
|
|
Ticker Symbol & Exchange:
|
ACTI OMX Nordic
|
|
Investor Relations Contact:
|
Göran Forsberg
|
|
Investor Relations Contact Phone:
|
46 46 19 11 54
|
|
Web:
|
www.activebiotech.com
|
|
Date of Presentation:
|
20-May
|
|
|
|
|
Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company
focusing on research and development of pharmaceuticals. Active
Biotech has a strong R&D portfolio with pipeline products focused on
autoimmune/inflammatory diseases and cancer. Most advanced projects
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis,
as well as ANYARA for use in cancer targeted therapy, primarily
renal cancer. Further key projects in clinical development comprise
the three orally administered compounds TASQ for prostate cancer,
57-57 for SLE and RhuDex® for RA.
|
|
|
|
|
Company:
|
Addex Pharma SA
|
|
Ticker Symbol & Exchange:
|
ADXN
|
|
Investor Relations Contact:
|
Chris Maggos
|
|
Investor Relations Contact Phone:
|
41 22 884 15 11
|
|
Web:
|
www.addexpharma.com
|
|
Date of Presentation:
|
20/05/2008
|
|
|
|
|
Addex Pharmaceuticals Ltd discovers and develops allosteric
modulators, an emerging class of small molecule therapeutic agents.
Allosteric modulation may offer more sophisticated ways to normalize
biological signaling compared to classical orthosteric agonist or
antagonist drugs.
|
|
|
|
Lead product, ADX10059, a negative allosteric modulator (NAM) of
metabotropic glutamate receptor 5 (mGluR5), showed clinically and
statistically significant efficacy in separate Phase IIa clinical
trials in gastroesophageal reflux disease (GERD) and migraine. The
company has 12 early stage products.
|
|
|
|
The Addex allosteric modulation discovery and development platform
has been additionally validated through product collaborations with
Merck & Co., Inc. and Johnson & Johnson.
|
|
|
|
|
Company:
|
Biosante Pharmaceuticals, Inc.
|
|
Ticker Symbol & Exchange:
|
BPAX/NASDAQ
|
|
Investor Relations Contact:
|
Phillip Donenberg
|
|
Investor Relations Contact Phone:
|
847-478-0500 ext 100
|
|
Web:
|
www.biosantepharma.com
|
|
Date of Presentation:
|
19-May-08
|
|
|
|
|
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health, menopause, contraception and male
hypogonadism. BioSante's lead products include LibiGel®
(transdermal testosterone gel) in Phase III clinical development by
BioSante under a U.S. Food and Drug Administration (FDA) SPA
(Special Protocol Assessment) for the treatment of female sexual
dysfunction (FSD), and Elestrin™
(estradiol gel) developed through FDA approval by BioSante,
indicated for the treatment of moderate-to-severe vasomotor symptoms
associated with menopause, currently marketed in the U.S. Also in
development are Bio-T-Gel™, a
testosterone gel for male hypogonadism, and an oral contraceptive in
Phase II clinical development using BioSante patented technology.
|
|
|
|
|
Company:
|
Cyclacel Pharmaceuticals, Inc.
|
|
Ticker Symbol & Exchange:
|
CYCC
|
|
Investor Relations Contact:
|
Corey Sohmer
|
|
Investor Relations Contact Phone:
|
1 908 517 7330
|
|
Web:
|
www.cyclacel.com
|
|
Date of Presentation:
|
May 20th
|
|
|
|
|
Cyclacel is a diversified biopharmaceutical business dedicated to
the discovery, development and commercialization of novel, targeted
drugs to treat cancer. Cyclacel’s
strategy is focused on leading edge therapeutic management of cancer
patients based on a portfolio of three medicines marketed by its
ALIGN subsidiary and a deep development pipeline. Three
orally-available drugs are in clinical development: sapacitabine (in
two randomized Phase 2 studies for the treatment of elderly acute
myeloid leukemia and cutaneous T-cell lymphoma); seliciclib (in two
randomized Phase 2 studies for the treatment of lung and
nasopharyngeal cancers) and CYC116 (in Phase 1 in patients with
solid tumors).
|
|
|
|
|
Company:
|
Cytori Therapeutics
|
|
Ticker Symbol & Exchange:
|
CYTX
|
|
Investor Relations Contact:
|
Tom Baker
|
|
Investor Relations Contact Phone:
|
858.458.0900
|
|
Web:
|
www.cytoritx.com
|
|
Date of Presentation:
|
5.19.08
|
|
|
|
|
Cytori Therapeutics' (NASDAQ:CYTX) goal is to be the global leader
in regenerative medicine. The company is dedicated to providing
patients with new options for reconstructive surgery, developing
treatments for cardiovascular disease, and banking patients' adult
stem and regenerative cells. The Celution®
800 System is being introduced in Europe into the reconstructive
surgery market while the Celution™ 900
System will be launched in Asia-Pacific for cryopreserving a
patient's own stem and regenerative cells. Clinical trials are
ongoing in cardiovascular disease and planned for spinal disc
degeneration, gastrointestinal disorders, and other unmet medical
needs. www.cytoritx.com
|
|
|
|
|
Company:
|
DOV Pharmaceutical, Inc.
|
|
Ticker Symbol & Exchange:
|
DOVP.OB
|
|
Investor Relations Contact:
|
Barbara Duncan
|
|
Investor Relations Contact Phone:
|
732-907-3604
|
|
Web:
|
www.dovpharm.com
|
|
Date of Presentation:
|
19-May-08
|
|
|
|
|
DOV is a biopharmaceutical company focused on the development of
novel product candidates for disorders of the central nervous
system, or CNS. We currently have drug development programs that
are at the preclinical, Phase I and Phase II clinical stages,
including DOV 21, 947 (in a Phase II clinical trial for
depression), DOV 102,677 (which has completed a Phase I clinical
trial) and a preclinical discovery program in reuptake inhibitors
and GABA modulators.
|
|
|
|
|
Company:
|
Evotec AG
|
|
Ticker Symbol & Exchange:
|
FSE:EVT, NASDAQ:EVTC
|
|
Investor Relations Contact:
|
Anne Hennecke
|
|
Investor Relations Contact Phone:
|
49-40-56081-286
|
|
Web:
|
www.evotec.com
|
|
Date of Presentation:
|
May 20, 2008, 11.00 am CET
|
|
|
|
|
Evotec is a leader in the discovery and development of novel small
molecule drugs. In proprietary projects, Evotec specializes in
finding new treatments for diseases of the CNS. Evotec has 3
programs in clinical development: EVT201, a partial positive
allosteric modulator of the GABA-A receptor complex for the
treatment of insomnia, EVT101, a subtype selective NMDA receptor
antagonist for the treatment of Alzheimer's disease and/or pain, and
EVT302, a MAO-B inhibitor in development for smoking cessation.
Evotec's proprietary preclinical research programs focus on the
purinergic receptors, P2X3 and P2X7, for the potential treatment of
pain and inflammatory diseases. In addition, Evotec has worldwide
collaboration and license agreements with Pfizer to research,
develop and commercialize small molecule vanilloid receptor (VR1)
antagonists.
|
|
|
|
|
Company:
|
FIBREX MEDICAL Inc.
|
|
Investor Relations Contact:
|
Rainer Henning, President & CE
|
|
Investor Relations Contact Phone:
|
43-1-86634-9270
|
|
Web:
|
www.fibrexmedical.com
|
|
Date of Presentation:
|
20-May
|
|
|
|
|
FIBREX MEDICAL is a develo |
